Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anjali James"'
Autor:
Sudpreeda Chainitikun, Akshara Singareeka Raghavendra, Kumiko Kida, Daniel L. Adams, Maryanne E Sapon, Andrea Yd Medrano, Tushaar Vishal Shrimanker, Naoto T. Ueno, Cha-Mei Tang, Toshiaki Iwase, Ann H. Klopp, Onur Sahin, Aaroh M. Parikh, Anjali James
Publikováno v:
Cancer Research. 81:PS2-23
Background Cancer-associated macrophage-like cells (CAMLs) are rare circulating gigantic atypical cells exclusively found in the peripheral blood of patients with solid cancers. CAMLs potentially originate from tumor-associated macrophages in the tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48bdc33edaae0cd86befeda531215a3f
https://doi.org/10.1158/1538-7445.sabcs20-ps2-23
https://doi.org/10.1158/1538-7445.sabcs20-ps2-23
Autor:
Anjali James, Ruben Rodriguez-Bautista, Yu Shen, Naoto T. Ueno, Jimin Wu, Toshiaki Iwase, Onur Sahin, Tushaar Vishal Shrimanker
Publikováno v:
Cancers
Volume 13
Issue 11
Cancers, Vol 13, Iss 2650, p 2650 (2021)
Volume 13
Issue 11
Cancers, Vol 13, Iss 2650, p 2650 (2021)
The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort study with 1981 patients with dnMBC diagnosed between January 199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d7382bc0875c3e3e60ccef78dd2205d
Autor:
Sachiyo Tada, Tomoko Matsushima, Robert Schuetz, Seigo Nakamura, Yasuto Naoi, Debu Tripathy, Yuki Matsunaga, Jose Rodrigo Espinosa Fernandez, Jared David Acoba, Yee Chung Cheng, Aysegul A. Sahin, Keisuke Yamagishi, Fei Yang, Rubie Sue Jackson, Takeo Fujii, Hiroko Masuda, Naoto T. Ueno, Arup Kumar Sinha, Shinzaburo Noguchi, Akshara Singareeka Raghavendra, Anjali James
Purpose A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1005a191ee9e036668737ba00ca52c4
https://doi.org/10.21203/rs.3.rs-496843/v1
https://doi.org/10.21203/rs.3.rs-496843/v1
Autor:
Andrea Y. Delgado Medrano, Ann H. Klopp, Toshiaki Iwase, Naoto T. Ueno, Aaroh M. Parikh, Sudpreeda Chainitikun, Maryanne E Sapon, Onur Sahin, Tushaar Vishal Shrimanker, Yu Shen, Anjali James, Seyedeh Dibaj, Kumiko Kida
Publikováno v:
Cancers, Vol 13, Iss 608, p 608 (2021)
Cancers
Volume 13
Issue 4
Cancers
Volume 13
Issue 4
Simple Summary We aimed to determine the prognostic role of body composition in patients with breast cancer who received neoadjuvant chemotherapy. Previous studies suggested that body composition is a better indicator of breast cancer treatment outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded221071cc98dd685400aa8574eeefc
https://www.mdpi.com/2072-6694/13/4/608
https://www.mdpi.com/2072-6694/13/4/608
Autor:
Anjali James, Charles Mylander, JR Espinosa Fernandez, Lorraine Tafra, Rubie Sue Jackson, Arup Kumar Sinha, Martin Rosman, Michele M. Gage, Takeo Fujii, Akshara Singareeka Raghavendra, F Le Du, NT Ueno
Publikováno v:
Cancer Research. 78:P3-09
Introduction: The 21-gene recurrence score (RS) assay categorizes hormone receptor positive, node negative breast cancers (BC) into 3 risk groups for recurrence. We previously showed that the AAMC Model, using only standard pathology data, accurately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f2f972bbc3061f8cc060f8b1a1f855
https://doi.org/10.1158/1538-7445.sabcs17-p3-09-05
https://doi.org/10.1158/1538-7445.sabcs17-p3-09-05
Autor:
Anjali James, W. C. Mylander, JR Espinosa Fernandez, Martin Rosman, Rubie Sue Jackson, Akshara Singareeka Raghavendra, NT Ueno, Arup Kumar Sinha, M. M. Gage, F Le Du, Lorraine Tafra, Takeo Fujii
BACKGROUND: The 21-gene recurrence score (RS) (Oncotype DX(®); Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead06a18df53498ade2377ca034f4e5b
https://europepmc.org/articles/PMC5961181/
https://europepmc.org/articles/PMC5961181/
Autor:
Anjali James, Yuki Matsunaga, Rubie Sue Jackson, Arup Kumar Sinha, Shinzaburo Noguchi, Fei Yang, Jose Rodrigo Espinosa Fernandez, Keisuke Yamagishi, Jared David Acoba, Naoto T. Ueno, Takeo Fujii, Akshara Singareeka Raghavendra, Aysegul A. Sahin, Debu Tripathy, Sachiyo Tada, Tomoko Matsushima, Yasuto Naoi, Seigo Nakamura, Hiroko Masuda, Yee Chung Cheng
Publikováno v:
Journal of Clinical Oncology. 37:542-542
542 Background: The TAILORx trial demonstrated that adjuvant endocrine and chemoendocrine therapies had similar efficacy in patients with hormone receptor-positive, HER2-negative, node-negative breast cancer with an Oncotype DX recurrence score (RS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f005fe68b7e863cc1d8043727a36770
https://doi.org/10.1200/jco.2019.37.15_suppl.542
https://doi.org/10.1200/jco.2019.37.15_suppl.542
Autor:
ANJALI JAMES
Publikováno v:
The Nursing journal of India. 88(10)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::905376dcd3227af71b5d8685ccabf755
https://pubmed.ncbi.nlm.nih.gov/9444225
https://pubmed.ncbi.nlm.nih.gov/9444225